UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013033
Receipt number R000015211
Scientific Title Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis.
Date of disclosure of the study information 2014/02/01
Last modified on 2014/01/31 14:22:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis.

Acronym

Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis

Scientific Title

Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis.

Scientific Title:Acronym

Examination of the early clinical and endoscopic views change after infliximab administration in the ulcerative colitis

Region

Japan


Condition

Condition

Ulcerative colitis

Classification by specialty

Medicine in general Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We examine a change of disease activity, the endoscope evidence in the early stage of the Infliximab administration for the moderate disease (steroid-dependent resistance) of ulcerative colitis, usefulness of marker "fecal calprotectin" for the colonoscope.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Mayo score percent improvement 6-14 weeks after the administration.

Key secondary outcomes



Base

Study type


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Device,equipment

Interventions/Control_1

Study start - 14 weeks:5mg/kg of Infliximab for 0.2.6.14 week, respectively ( initial administration day with 0 weeks)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. The patients with steroid dependence, resistant ulcerative colitis moderate disease.(Mayo Score 6-10)
2. Being 20 years old or older
3, A document agreement by the free will of the patients person himself being obtained in the thing which understands it enough after having received enough explanation on participating of this study

Key exclusion criteria

1. The patients with serious infection (sepsis)
2. The patients with active tuberculosis
3. The patients with a history of sensitivity to protein(mouse type, a chimeric type, humanized antibody) derived from a mouse or ingredient of the Infliximab
4. The patients with a history of demyelinating diseases (Multiple sclerosis)
5. The patients with congestive heart failure
6. The patients that doctor attending judged an arrangement to this study to be inappropriate

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Taro Osada

Organization

Department of Internal Medicine,Juntendo University

Division name

Department of Gastroenterology

Zip code


Address

2-1-1 Hongo,Bunkyo ward,Tokyo,Japan

TEL

0338133111

Email

otaro@juntendo.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Taro Osada

Organization

Department of Internal Medicine,Juntendo University

Division name

Department of Gastroenterology

Zip code


Address

2-1-1 Hongo,Bunkyo ward,Tokyo,JapanTokyo Japan

TEL

03-3813-3111

Homepage URL


Email

otaro@juntendo.ac.jp


Sponsor or person

Institute

Department of Internal Medicine,Juntendo University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2014 Year 01 Month 31 Day

Date of IRB


Anticipated trial start date

2014 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 01 Month 31 Day

Last modified on

2014 Year 01 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015211


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name